Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AFT Pharmaceuticals Ltd. ( (AU:AFP) ) just unveiled an update.
AFT Pharmaceuticals reported sustained double-digit sales growth across all markets for FY26, setting up record annual sales and confirming operating earnings guidance of $20 million to $24 million. The company reiterated it is on track to reach its FY27 revenue target of $300 million, underpinned by strong demand in established hubs and continued expansion into markets with dynamics similar to Australasia.
Strategically, AFT strengthened its U.S. presence by partnering with Mark Cuban-backed Cost Plus to distribute its Maxigesic Rapid (Combogesic Rapid) tablets, while maintaining existing distribution arrangements for other product formats. In South Africa, the integration of the acquired Pharma Dynamics hospital business has quickly expanded AFT’s product portfolio and is expected to materially boost revenue and earnings from FY27.
The company also advanced its novel injectable iron treatment following successful engagement with the U.S. FDA and completion of a clinical study showing benefits versus existing oral and intravenous therapies. AFT is preparing a pivotal global trial, co-funded with partner Hyloris, and is simultaneously broadening its over-the-counter iron range, reinforcing its pipeline across pain, dermatology, eyecare, and injectables to support future growth.
Despite global uncertainties, AFT signalled a positive outlook, citing broad-based growth, elevated inventory to safeguard supply, and a robust regulatory push with at least 70 new product registrations filed annually across its affiliates. Management indicated these initiatives are aligned with achieving the FY27 $300 million revenue goal and sustaining the company’s growth trajectory in key international markets.
More about AFT Pharmaceuticals Ltd.
AFT Pharmaceuticals is a New Zealand-based multinational pharmaceuticals company that develops, markets, and distributes a broad portfolio of proprietary and in-licensed medicines across over-the-counter, prescription, and hospital channels. Its products, including the Maxigesic pain relief range and an expanding iron supplement portfolio, are sold in core markets such as Australia, New Zealand, Asia, North America, and Europe, with additional out-licensing to partners in more than 125 countries worldwide.
For detailed information about AFP stock, go to TipRanks’ Stock Analysis page.